MEDIANTECHNOLOGIES overview

Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 18,757,159 Number of real voting rights* (excluding treasury shares**) 18,695,888 Theoretical number of voting rights* (including treasury shares**) 18,733,959 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF’s General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to...

Regulatory News: The shareholders of Median Technologies ( FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”) are invited to participate in the Shareholders’ Extraordinary General Meeting which will be held on Thursday March 20, 2025, at 10:15 am CET at PDGB, 174 avenue Victor Hugo – 75116 Paris. All useful information relating to this Shareholders’ General Meeting is regularly updated on Median Technologies’ website. Shareholders may exercise their voting...

Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”) , a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, announced today that it will participate in TD Cowen’s 45 th Annual Health Care Conference, taking place March 3-5...

Regulatory News: Median Technologies ( FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”) , a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, today announced that it will attend the European Congress of Radiology (ECR) 2025 in Vienna, from Feb. 26 to March...

Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares 18,631,386 Number of real voting rights* (excluding treasury shares**) 18,567,201 Theoretical number of voting rights* (including treasury shares**) 18,608,186 (*) Class E preference shares are non-voting (**) pursuant to article 223-11 of the AMF’s General Regulations About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to...

Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME scheme eligible), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-based image analyses and imaging services for oncology drug developers, announced that, on January 23, 2025, the Company signed a financing agreement with Iris in the form of bonds redeemable in shares for a maximum amount of...

Regulatory News: Median Technologies (Paris:ALMDT): Fredrik Brag, CEO of Median Technologies, will host two webcasts on February 4, 2025 “New Horizons in Fighting Lung Cancer: eyonis™ LCS RELIVE study results and next steps towards marketing authorizations” February 4, 2025 – 2:00 pm CET (French): Sign-up Link February 4, 2025 – 4:00 pm CET / 10:00 am EDT (English): Sign-up Link Webcast replays will be available on Median’s corporate website shortly after the live sessions. Median...

Regulatory News: Median Technologies ( FR0011049824, ALMDT, PEA/SME scheme eligible), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-based image analyses and imaging services for oncology drug developers, releases today its 2024 key financial indicators (unaudited), and provides an outlook on the Company’s critical milestones in 2025. Fredrik Brag, Chief...